Frank Neumann, M.D., Ph.D. Chief Medical Officer

Dr. Frank Neumann brings a record of proven leadership in cell therapy and oncology clinical development to his role as Chief Medical Officer.

Prior to joining Orna, Frank most recently served as Senior Vice President and Global Head of Clinical Development at Kite, a Gilead Company. He previously held positions as Chief Medical Officer at Verastem, Inc. (also known as Verastem Oncology) and as Vice President, Head of Oncology Clinical Research at bluebird bio. In addition, Frank was clinical development head of all global cell therapy approaches at Takeda Pharmaceuticals, where he held various leadership roles of increasing prominence, including global clinical lead and medical team lead for two distinct cancer therapies. Earlier in his career, he was a member of the oncology medical teams at AstraZeneca and Sanofi-Aventis.

Board certified in Hematology/Oncology, Internal Medicine and Palliative Care Medicine, Frank was a research scholar at the University of Texas MD Anderson Cancer Center and is currently an assistant professor at the Heinrich Heine University in Düsseldorf, Germany, where he received his M.D. He earned his Ph.D. from the Rheinische-Friedrich-Wilhelm University in Bonn, Germany. In addition to his role with Orna, Frank is an Entrepreneur Partner with MPM BioImpact.